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Introduction
The rational design of innovative metal-containing compounds has been a major goal in cancer research in recent years. While initially most of the studies have been largely focusing on platinum compounds, more recently other noble metals, like gold, osmium and ruthenium have attracted attention [1, 2] . Also silver(I) complexes containing various types of ligands, including carboxylic acids, amino acids, nitrogen-, phosphorus-, or sulfur-donor ligands, have been prepared and studied for their antitumor activity [3, 4] . In fact, some of them exhibit significant in vitro antiproliferative properties [3, 4] . Interestingly, for the kinetically more labile first-row transition metals, coordination compounds are known that hold great potential as anticancer agent, and earlier studies supported their drug design [5] [6] [7] [8] . Earlier studies by Sigman in the 1990s [9] [10] [11] [12] [13] , and by Pitié and Meunier [14] [15] [16] and several others in recent years [17] [18] [19] [20] [21] [22] [23] indicate efficient DNA cleavage and cytostatic properties. Such compounds are also reported to display antiangiogenic activity [24] . Also, studies by some of us with Cu(II) compounds and tridentate pyridine-based ligands have shown very promising results for both DNA cleavage and anticancer activities [25] [26] [27] [28] .
Within this frame, the results by Ruiz et al. hold great promise, and include the group of metal compounds named casiopeinas, copper-based coordination complexes with generic structure of [Cu(N-N)(O-N)] + or [Cu(N-N)(O-O)] + that have proven cytotoxic to cancer cells sensitive or resistant to cisplatin, and to xenograph tumors in mice [29, 30] , and are now in clinical trials. The mode of action for casiopeinas is largely unknown, but it has been suggested that mitochondrial permeability transition may be important [31] , as well as DNA damage [32] and others [33] .
In general, investigation of first-row transition metal complexes as cytotoxic agents has received increasing attention, because of the development of metallodrugs containing endogenous metal ions (instead of non-physiological ones, with potentially severe side effects) is attractive.
Therefore, many studies have been reported during the last 5 years, including those disclosing the 3D structure of the respective compounds [5, 34, 35] . Nevertheless, the mode of action of such metal complexes is still poorly understood; nucleic acids and proteins are likely targets [36] [37] [38] [39] . For example, Cu(II), Co(II) and Zn(II) complexes featuring the quinolone antibacterial drug flumequine and N,N'-donor heterocyclic compounds as ligands have also been demonstrated to be able to interact with nucleic acids and serum albumin [40] [41] [42] [43] . Instead, cytotoxic Co(III) complexes with substituted phenanthrolines have shown weak binding to nucleic acids [40] .
Based on the above-mentioned considerations, in order to design new first-row transition metal compounds with enhanced thermodynamic stability in aqueous solution and with possible antiproliferative activity, we have selected the ligand norharmane (9H-Pyrido [3,4-b] indole, abbreviated as Hnor and depicted in Scheme 1), consisting of a fused-ring heterocyclic compound that belongs to the alkaloid family β-carbolines (βCs). This molecule has been known for over 50 years [44] [45] [46] [47] [48] [49] , but it is still poorly studied. It has a remote H-bond donor group, in addition to the metal binding site, and so far it has only been used to coordinate Ru(II) ions [49] and more recently silver(I) ions [50] . In addition to coordination, also other weak forces, like hydrogen bonding and intermolecular non-covalent interactions should be taken into account [51] [52] [53] [54] [55] . In this respect Hnor appears to have a suitable structure to bind metal compounds, where coordination, H-bonding and π-π stacking may act in synergy. Interestingly, so far a wide spectrum of biological, psychopharmacological, and toxicological activities have been reported for Hnor, e.g. anticancer [56] , binding to benzodiazepine receptors [57] , inhibition of monoamine oxidase [58] , and DNA topoisomerase I and II [59] .
Despite the fact that several known transition-metal compounds display antiproliferative properties, the combination of certain metals and different (potentially) intercalating ligand remains challenging and worth studying.
Following our recent promising results with Ag(I) complexes of Hnor [50] , we have extended here our study to first-row transition metals, and simultaneously added a polypyridine co-ligand, i.e.
2,2'-bipyridyl (bpy), or 1,10-phenanthroline (phen), which are known to be able to interact with DNA and also possess cell-growth inhibition properties [60] . Thus, we report here on the synthesis and characterization of eight new coordination compounds containing the ligands Hnor and 1,10phenantroline (phen)/2,2'-bipyridyl (bpy) bound to Cu(II), Co(II), Ni(II) and Zn(II) ions (Scheme 1).
Notably, the NO 3 anion was chosen for charge neutrality and as an additional ligand, as this is a potentially weakly coordinating anion, and it is at the same time prone to H-bond acceptance. Thus, the potentially tridentate anionic ligand NO 3 may act in both monodentate and chelating forms to complete the metal coordination sphere [61] . X-ray diffraction studies allowed elucidating the structure of the copper complex, with phen as co-ligand, 1.
Some of the obtained compounds were tested for their effects on cell viability against two human cancer cell lines, and evaluation of their apoptotic effects was performed by flow-cytometry.
In order to study transport of the compounds via copper transporters, the effects of addition of "free"
Cu(II) to the cell culture medium were also evaluated; this is a classical competition experiment to assess transport mechanisms [62] , but allowed also to relate the observed biological activity to the stability of the metal compounds in solution.
Scheme 1 -Schematic description of the metal compounds with Hnor and phen/bpy ligands used in this study.
Experimental Part

Starting Materials and methods
Metal nitrate salts were all used as commercially available; tryptophane was obtained as a racemic mixture and used as obtained. Other standard laboratory chemicals were used as available. Cisplatin was purchased from Sigma. Infrared spectra were recorded as KBr pellets, using a Shimadzu IRAffinity-1 spectrometer with a resolution of 4 cm -1 . Ligand field spectra were performed on solid powders (room T, diffuse reflectance mode) in the range 200-1100 nm.
Elemental analysis (C,H,N) were performed on a PerkinElmer 2400 Series II CHNS/O system. NMR spectra in DMSO solution were recorded using a JEOL-ECP-400 spectrometer.
Synthesis
The ligand norharmane (Hnor) was synthesized from tryptophane and formaline as described by us before [55] according to the method of Snyder et al. [53] . Yield Transition-metal compounds 1-8 (see Scheme 1) with the ligand Hnor were prepared by dissolving the metal salt and Hnor (1:1) in methanol (MeOH) and adding a co-ligand bpy or phen (also in the ratio 1:1). A typical recipe is as follows: 2,2'-Bipyridyl/1,10-phenanthroline (1 mmol) was added to the solution of metal salts (1 mmol) in MeOH, and after 30 min of stirring, Hnor (1 mmol) was added to the mixture and allowed to stir for 12 h and then kept for slow evaporation. The crystalline product obtained was washed with CH 2 Cl 2 , ether, hexane. The product obtained was dissolved in a MeOH/acetonitrile mixture for re-crystallization.
The new compounds are listed below with their color and elemental analysis and relevant IR and UV data. Preliminary orientation matrices, unit cell determination, data reduction and absorption correction were performed using CrystalClear package [63] . The data were empirically corrected for Lorentz and polarization effects. The structure was solved by direct methods and refined by full-matrix least squares on all |F 2 | data using SHELX package [64] . Aromatic hydrogen atoms were isotropically refined and constrained to ideal geometry, using their appropriate riding model and non-hydrogen atoms were anisotropically refined. The Hnor hydrogen atom on N involved in hydrogen bonding was located from difference Fourier map and refined with distance restraint. One of the nitrate oxygen atoms was found disordered over two positions and refined with a split-atom model of 0.54/0.46 occupancy factor. The descriptive crystallographic figures were created using the DIAMOND package [65] . All relevant crystallographic data are summarized in Table 1 . Powder Xray diffraction of the Cu(II) phen compound (1) have shown a homogenous phase compared to the pattern simulated from the single-crystal diffraction. 
Compounds with phen (1,10-phenanthroline) as a co-ligand
Cell viability assay
The 
UV-vis spectrophotometry in solution
Dilutions of each metal compound were obtained from freshly prepared stock solution (10 -2 M in DMSO) and added to a 96-well plate. To these solutions, either CuCl 2 (from a stock solution of 10 -1 M in MiliQ water) or MilliQ water were added. The final ratio of compound versus CuCl 2 was 1:4.
The absorption spectra were recorded between 300-900 nm by spectrophotometry (Synergy H1
Hybrid reader, BioTek®) at various time points over 24 h at 37 °C. Obtained values were corrected for two baselines, with and without CuCl 2 .
Results and discussion
Synthesis and characterization
The Figures S17-20 in the supplementary material). The signal appeared at ~11.8 ppm was attributed to NH proton; the characteristic aromatic protons are displayed in the range of ~9-7 ppm (for details, see experimental section above). The signals show marked shifts when compared with the ligand "Hnor" alone. 13 C NMR of 7 and 8 complexes was also performed at 100 MHz, which showed all the peaks in the aromatic region of ~140-110 ppm as expected (depicted in Figures S21 and S22, in the supplementary material) . Thus, all the peaks were observed in accordance with the proposed structure.
Description of the molecular structure for compound 1 The molecular structure of compound 1 was studied using X-ray single crystal diffraction analysis. Descriptive molecular and packing diagrams are presented in Figure 1 and selected geometrical data are summarized in Table 2 . Thermal ellipsoid are at the 50% probability level and hydrogen atoms are represented as spheres of arbitrary radii. (8) In 1, the Cu(II) is coordinated in a distorted octahedral way, by a bidentate phen, a monodentate Hnor, a monodentate nitrate and a chelating bidentate nitrate. The Hnor ligand coordinates with the pyridine nitrogen, whereas the N-H group of the ligand, donates a hydrogen bond (intermolecularly) to the coordinated O of the bidentate nitrate of a nearby molecule in C (7) first level chain motif along the [010] base vector, with an N----O contact distance of 3.02(4) Ȧ. The monodentate nitrate is found disordered over 2 rotational positions. The coordination mode of Hnor agrees with our previously found [50] binding to Ag(I) and also with the only transition-metal compound (Ru) known so far for this ligand [49] . Nitrates are well known to be able to coordinate in different modes to metal ions, be it monodentate or bidentate, and two different binding modes in the same compound are also known for quite some time [67] . Given the fact that the ligand has several bands in the 1300-1500 cm -1 wavelength range, it was not possible to discriminate between the possible binding modes and mixtures of them from IR. However, given the overall similarities in the IR spectra, we have assumed that the binding modes of the Co, Ni and Zn compounds are similar to that of the Cu(II) compound.
Cytotoxic properties
The antiproliferative properties of the ligand Hnor and the metal complexes 1-5 and 7 (with cisplatin used as a comparison) were assessed by monitoring their ability to inhibit cell growth using the classical MTT assay in human ovarian (A2780) and lung cancer (A549) cell lines. Table 3 summarizes the obtained IC 50 data, and Fig. 2 shows representative effects on cell viability for Concerning the other complexes with 1,10-phenanotroline ligands, the antiproliferative activities followed the order 7 (Zn) > 3 (Co) >> 5 (Ni). In general, the compounds 2 and 4 (with the bipyridine ligand) were found less effective than their phen analogues. It should be noted that the phen ligand exerts itself important antiproliferative effects, followed by the bpy ligand. Instead, the free Hnor ligand is not toxic in both the tested cell lines (IC 50 > 200 µM) (Table 3) . Notably, the biological activity of 1 and 2 is not only due to the presence of Cu(II) ions, but to the overall compounds'
chemico-physical properties (e.g. hydrophilic/lipophilic balance and stability) which may lead to its enhanced accumulation in cancer cells. In fact, treatment of cancer cells with CuCl 2 did not show any toxic effect at concentrations higher than 200 M (Table 3 ). CTR1) have been shown to be involved in the cellular import of Pt(II) chemotherapeutic agents in cancer cells, as well as in their resistance mechanisms [70] . In order to study transport of the compounds via copper transporters, the effects of addition of "free" Cu(II) ions to the cell culture medium were also evaluated. Thus, we co-administered complexes 1-5 and 7 with non-toxic concentrations of CuCl 2 (a competitor for transport via hCTR1), at the highest non-toxic dose (20 M) , and evaluated the effects on proliferation after 24 or 72 h incubation. If the uptake of the metal compounds goes via the same route as for Cu 2+ , then we would expect a reduced toxic effect due to reduced uptake of metal compounds in cancer cells. However, as it is shown in Table 3 , the addition of CuCl 2 increases the activity of both copper and cobalt compounds. This effect is especially dramatic for the Co 2+ compound 3 in both cell lines, where IC 50 values change from the compound being not active to one of the most potent of the series (see Figure 2 above). Given the fact that Cu(II) is a very strong ligand binder, this would suggest that in these cases the Cu(II) compound is largely responsible for the observed activity. should induce metal exchange and formation of the most stable copper complex. The propensity of this reaction to occur should follow the order Co(II) > Ni(II) > Cu(II) < Zn(II). This is reflected not only by the UV-vis data but also by the trend in the cytotoxic effects. In fact, the Co complexes are those that have the highest increase in antiproliferative activity after co-incubation with CuCl 2 (ca. 10-fold: IC 50 of 3 = 12.70 ± 0.97 M and of (3 +CuCl 2 ) = 0.83 ± 0.29 M, respectively; see Figure 2 ).
Noteworthy, the value for the (3 +CuCl 2 ) is comparable to the IC 50 calculated for 1 (IC 50 = 1.88 ± 0.21 M), consistent with the formation of Cu complexes in the cell culture medium. It is worth mentioning that metal complex instability in aqueous media, favored by the addition of Cu(II) ions, may also affect the concentration of "free" phen ligand which is also toxic. Similar effects are observed for the Co-bpy analogue 4. The effect of CuCl 2 on the nickel complex 5 is more moderate (only ca. 3-fold increase in potency) in accordance with the higher stability of the compound with respect to metal substitution. Although reactivity of the zinc complex, 7, with CuCl 2 could also be observed via absorption spectroscopy, since the zinc complex, 7, is already per se very cytotoxic, marked effects induced by addition of CuCl 2 could not be recorded, and we cannot even exclude that 7 may be exerting important effects per se. Nevertheless, it is also possible that metal substitutions may also occur in vivo in the presence of physiological copper ions already available in the cell culture medium. Finally, just as expected the biological effects of the copper complexes, 1-2 do not vary substantially in the presence of CuCl 2 . 
Concluding Remarks
Heterocyclic ligands with N-donor groups and nearby N-H groups have shown to be an interesting ligand series to be used in binding studies with metal ions where the coordination to transition metal ions can also be influenced by hydrogen bonding of the N-H group to e.g. anions;
as mentioned, such a phenomenon is already known and described [55] . As for pyrazoles, for all the reported compounds, intramolecular H bonds are also visible, as shown by XRD and deduced from IR; while intermolecular hydrogen bonding to the anion must also occur. Concerning the anticancer
properties, it appears that the marked antiproliferative activity of the copper complexes 1-2 and of the zinc compound 7 has to be ascribed to at least the presence of significant amounts of the metal in combination with both ligands. Overall, this trend in activity is in accordance with previously reported studies on similar first-row transition metal compounds [61] . While transport of the reported compounds via copper transporters may be excluded, our results allowed to identify the most active divalent metal complexes within the first-row transition metals, which can be related to the order of stability within the Irving-Williams series. Further studies are necessary to identify the pathways leading to apoptosis. However, it is worth mentioning that, inside the living cell, metal binding and redox events enter into an exciting, and highly complicated interplay, often resulting in extensive cellular signaling pathways and control networks. Thus, the application of coordination compounds of endogenous metal ions may be even more relevant to induce important intracellular alterations at physiological concentrations. Although the mechanism of antiproliferative activity is not well established for kinetically labile metal ions, the observed biological effects of these complexes, also as a result of the competition with other endogenous metal ions for ligand binding, appears as promising. 
